Group 1: Financial Performance - The company achieved a revenue of 713 million CNY, representing an increase of 11.02% compared to the same period last year [3] - Medical device business revenue reached approximately 482 million CNY, growing by 13.8% [3] - The net profit attributable to shareholders was approximately 74 million CNY, with a year-on-year growth of about 20.99% after excluding stock incentive expenses and exchange losses [3] Group 2: Business Operations - The company focuses on management-style medical services, primarily in the liver disease sector, including drug production, diagnostic equipment development, and related medical services [3] - Echosens has installed a total of 977 units of its products globally [3] - The company is currently collaborating with Novo Nordisk to promote early diagnosis and treatment of Metabolic Associated Steatotic Hepatitis (MASH) [3] Group 3: Market Trends and Strategies - The approval of semaglutide for MASH is expected to enhance awareness and treatment options in the industry [3] - The company has stable internal shareholding and strategic plans, indicating no adjustments to its operational strategies [4] - E-commerce channels for traditional Chinese medicine have shown significant growth, with a year-on-year increase of 59.23% [4] Group 4: Future Outlook - The company's mission is to "keep every family away from liver cancer," focusing on a closed-loop management strategy to reduce liver cancer incidence [5] - There is confidence in the industry outlook and the company's development trajectory, supported by a clear organizational and shareholding structure [5]